In 2002, we released the anti-psychotic drug "ABILIFY" in the United States, our first original medication. Many antipsychotic drugs that were sold at that time had antagonist effects that inhibited the dopamine D2 receptor. However, ABILIFY works by suppressing dopamine neurotransmission when dopamine secretion is excessive, and activating it when there is deficient dopamine secretion, meaning that it has the world's first dopamine system stabilizer (DSS) mechanism.
CNS diseases and their treatments are often accompanied by adherence issues: patients may lack an understanding of their condition, dislike the side effects of their medication and stop taking it, or forget to take it. This often leads to relapses. For better patient outcomes and improved adherence, desirable antipsychotic medications are effective but also have minimal side effects. Due to its unique characteristics, ABILIFY has gained wide recognition and usage from doctors and patients worldwide, and is now used in approximately 60 countries and regions.